Merck's Withdrawal From Diabetes Drugs Research May Help Glenmark (India) "
This article was originally published in PharmAsia News
Glenmark Pharmaceuticals is expected to benefit from a recent announcement by Merck KGaA that the international drug-maker is stopping all research and development for diabetes drugs. Currently, Merck and the India-based Glenmark have a E190 million licensing deal for Glenmark's experimental diabetes treatment, GRC 8200. The deal would have given Merck the right to market the drug in Japan, Europe, and the United States while Glenmark retained the Indian rights. Merck already paid Glenmark E25 million for the drug when it was in initial clinical trials, last year. Since that time, GRC 8200 has progressed into later-stage human testing, making it much more attractive to investors. Now, with the return of the licensing rights, Glenmark may be able to sell the molecule for a higher price to a third-party. Despite Merck's withdrawal, development of the drug is expected to continue on schedule. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.